EUVIMEDEUVIMED entdecken
Multizentrische Studie

High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group)

Kageaki Watanabe iD, Keita Sasaki iD, Ryunosuke Machida, Junichi Shimizu, Yuki Yamane, Motohiro Tamiya, Shin Saito, Yuji Takada, Kiyotaka Yoh, Hiroshige Yoshioka, Haruyasu Murakami iD, Satoru Kitazono und 3 weitere

Japanese Journal of Clinical Oncology · 2024

DOI: 10.1093/jjco/hyae094 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Kageaki Watanabe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22, Honko…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Research Fund of National Federation of Health Insurance Societies, National Cancer Center Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment of lung cancer has made dramatic progress in the past decade, but due to the high cost of drugs, the total pharmaceutical cost has been rising explosively. There are currently no data available in Japan on which regimens are used, to what extent they are used, and what their total cost is.

Methods

Sixty Japanese centers belonging to the Lung Cancer Study Group of the Japan Clinical Oncology Group were surveyed for information about the first-line treatment for advanced lung cancer in practice from July 2021 to June 2022. Three types of cancer were included: driver gene mutation-negative NSCLC, EGFR mutation-positive NSCLC, and extensive-stage small cell lung cancer (ES-SCLC).

Results

Recent treatment costs for ICIs or ICI plus chemotherapy were about 20–55 times higher than those for conventional chemotherapy. Of the 3738 patients with driver gene aberration-negative NSCLC, 2573 (68.8%) received treatments with monthly cost of 500 000 Japanese yen (JPY) or more; 2555 (68.4%) received ICI therapy. Of the 1486 patients with EGFR mutation-positive NSCLC, 1290 (86.8%) received treatments with a monthly cost of 500 000 JPY or more; 1207 (81.2%) received osimertinib. ICI treatments with a monthly cost of 500 000 JPY or more were administered to 607 (56.3%) of 1079 patients with ES-SCLC. Elderly NSCLC patients received slightly more high-cost treatment than younger patients.

Conclusion

Recent treatments cost many times more than conventional chemotherapy. This study revealed that high-cost treatments were widely used in advanced lung cancer and some of high-cost treatments were used despite the lack of clear evidence. Physicians should pay attention to the cost of treatments they use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansJapanErbB ReceptorsMutationSmall Cell Lung CarcinomaDrug CostsImmune Checkpoint InhibitorsMaleFemaleAntineoplastic Combined Chemotherapy ProtocolsAged

Stichwörter der Autor:innen

epidermal growth factor receptor mutation-positive non-small cell lung cancerextensive-stage small cell lung cancerhigh-cost treatmentimmune checkpoint inhibitornonsmall cell lung cancer

Substanzen

ErbB ReceptorsImmune Checkpoint InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
  • JCOG Data Center/Operations Office, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
  • Department of Thoracic Oncology, Aichi Cancer Centre Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
  • Department of Thoracic Oncology, Saitama Cancer Center, 780, Komuro, Ina, Kitaadachi, Saitama, 362-0806, Japan.
  • Department of Thoracic Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka, 541-8567, Japan.
  • Department of Pulmonary Medicine, Sendai Kousei Hospital, 4-15 Hirosemachi, Aoba-ku, Sendai, 980-0873, Japan.

ORCID-Profile: Kageaki Watanabe, Keita Sasaki, Haruyasu Murakami, Hidehito Horinouchi, Yuichiro Ohe

Förderung

  • Research Fund of National Federation of Health Insurance Societies
  • National Cancer Center Research and Development Fund

Zitieren

APA

Watanabe, K., Sasaki, K., Machida, R., Shimizu, J., Yamane, Y., Tamiya, M., Saito, S., Takada, Y., Yoh, K., Yoshioka, H., Murakami, H., Kitazono, S., Goto, Y., Horinouchi, H., & Ohe, Y. (2024). High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group). Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae094

Vancouver

Watanabe K, Sasaki K, Machida R, Shimizu J, Yamane Y, Tamiya M, et al. High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group). Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae094

BibTeX
@article{Watanabe2024,
  author = {Watanabe, Kageaki and Sasaki, Keita and Machida, Ryunosuke and Shimizu, Junichi and Yamane, Yuki and Tamiya, Motohiro and Saito, Shin and Takada, Yuji and Yoh, Kiyotaka and Yoshioka, Hiroshige and Murakami, Haruyasu and Kitazono, Satoru and Goto, Yasuhiro and Horinouchi, Hidehito and Ohe, Yuichiro},
  title = {High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group)},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1093/jjco/hyae094}
}
Kostenlos starten →